先声药业(02096)今日盘中大涨5.01%,引发市场广泛关注。
消息面上,先声药业的脑细胞保护创新药先必新舌下片获得国家药品监督管理局批准上市,用于改善急性缺血性脑卒中所致的神经症状、日常生活活动能力和功能障碍。该药使用了双靶点作用机制,可显著减少卒中导致的脑细胞损伤。
先声药业之前在2020年就已获批上市了先必新注射剂剂型。此次先必新舌下片的获批,将与注射剂形成序贯治疗,有望覆盖卒中全病程,发挥协同效应。根据数据,我国卒中治疗药物市场规模超过1300亿元,且仍保持较快增长,先必新获批上市后有望快速放量。同时,先必新舌下片也计划开展全球多中心临床研究。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.